Chronic myelocytic leukemia (CML) affects adult population between the ages of 40 and 60 and is uncommon in children younger than 10 years. CML is detected based on a simple blood test that exhibits an abnormally high count of white blood cells. Chronic myelocytic leukemia is usually a rearrangement of two particular chromosomes known as Philadelphia chromosome, which produces an abnormal enzyme (tyrosine kinase) that is responsible for the abnormal growth pattern of the white blood cells in a human body. In Chronic myelocytic leukemia, most of the leukemia cells are produced in the bone marrow. Few leukemia cells are also produced in the spleen and liver. Chronic stage of myelocytic leukemia is characterized by the increases in the number of white blood cells or leukemia cells that fill the bone marrow and enter the human bloodstream.
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. It is a type of cancer that starts in the blood-forming cells of the human bone marrow and invades the blood. The leukemia cells undergo numerous changes as the disease progresses and inevitable to blast crisis. Massive enlargement of the spleen, fever and weight loss is the common symptom in blast crisis. Initially, CML affected patient become fatigued, weak, lose their appetite, reduce weight, develop a fever or night sweats, and notice a sensation of being full due to enlarged spleen. As CML progresses to blast crisis, the patient becomes sicker due to the decrease in number of red blood cells and platelets causing paleness, bruising, and bleeding. Various treatments available for CML are radiation therapy, blood cell transplantation and chemotherapy.
The leading competitors in Chronic Myelocytic Leukemia (CML) therapeutics market are AbbVie Inc, Altor BioScience Corp, arGEN-X BV, Array BioPharma Inc, Ascentage Pharma Group Corp Ltd, Atara Biotherapeutics Inc, Bayer AG, Bio-Path Holdings Inc, BioLineRx Ltd, BioSight Ltd, Boston Biomedical Inc and others. Geographically, the Chronic Myelocytic Leukemia (CML) therapeutics market is spread across Asia, Africa, Americas, Europe, Middle East and rest of the world.
According to the study “Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H1 2018”, the latest guide for Chronic Myelocytic Leukemia provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (Oncology), drug target, mechanism of action (MoA), route of administration (RoA) and molecule type involved for CML. It also describes the descriptive pharmacological action of the CML therapeutics, complete research, development history, latest news and press related reports. The guide is developed using data and information obtained from various researcher’s proprietary databases, company, university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press related reports. The most recent developments in Chronic Myelocytic Leukemia (CML) are captured and recorded on a real time basis.
Advanced medical technology has witnessed great changes in the field of Chronic Myelocytic Leukemia (CML) diagnostics that strengthens the performance of drug manufacturers globally. It was observed that Chronic Myelocytic Leukemia (CML) is undergoing a tremendous research in the area of therapeutics and drug administration. This growth is expected to continue at a moderate pace over the next few years.
To know, more click on the link below:
Related Reports:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
0124-4230204
